伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究
|
摘要
目的评价晚期结直肠癌患者采用伊立替康联合替吉奥治疗的临床疗效。方法选取2015年4月～2017年12月我院肿瘤科收治的60例晚期初治结直肠癌患者作为研究对象,根据治疗方案的不同分为联合治疗组(32例)和对照组(28例)。对照组采用伊立替康治疗方案,在对照组基础上联合治疗组联合替吉奥治疗方案,比较两组的不良反应发生率及疗效情况。结果治疗后,联合治疗组的临床有效率高于对照组,差异有统计学意义(P<0.05);两组患者的主要不良反应比较,联合治疗组白细胞减少及胃肠道反应发生率较对照组降低,差异具有统计学意义(P<0.05)。结论晚期结直肠癌患者采用伊立替康联合替吉奥治疗方案优于单独采用伊立替康治疗方案,提高临床治疗的有效率,降低白细胞减少及胃肠道等不良反应的发生率。
Objective To evaluate the clinical efficacy of irinotecan plusTegafur,Gimeracil and Oteracil Porassium Capsulesin patients with advanced colorectal cancer.Methods 60 patients with advanced primary colorectal cancer admitted to our department of oncology from April 2015 to December 2017 were enrolled in the study. They were divided into the combination treatment group(32 cases) and the control group(28 cases).The control group was treated with irinotecan. On the basis of the control group, the combined treatment group was treated with a combination of Tegafur,Gimeracil and Oteracil Porassium Capsulesand the incidence of adverse reactions and efficacy were compared between the two groups. Results After treatment, the clinical effective rate in the combined treatment group was higher than that in the control group, the difference was statistically significant( P<0.05).The main adverse reactions in the two groups were compared with the leukopenia in the combined treatment group. The incidence of gastrointestinal reactions was lower than that of the control group,the difference was statistically significant( P<0.05). Conclusion The treatment of irinotecan plus Tegafur,Gimeracil and Oteracil Porassium Capsules in patients with advanced colorectal cancer is superior to irinotecan alone in improving the efficiency of clinical treatment and reducing the incidence of leukopenia and gastrointestinal reactions.
Objective To evaluate the clinical efficacy of irinotecan plusTegafur,Gimeracil and Oteracil Porassium Capsulesin patients with advanced colorectal cancer.Methods 60 patients with advanced primary colorectal cancer admitted to our department of oncology from April 2015 to December 2017 were enrolled in the study. They were divided into the combination treatment group(32 cases) and the control group(28 cases).The control group was treated with irinotecan. On the basis of the control group, the combined treatment group was treated with a combination of Tegafur,Gimeracil and Oteracil Porassium Capsulesand the incidence of adverse reactions and efficacy were compared between the two groups. Results After treatment, the clinical effective rate in the combined treatment group was higher than that in the control group, the difference was statistically significant( P<0.05).The main adverse reactions in the two groups were compared with the leukopenia in the combined treatment group. The incidence of gastrointestinal reactions was lower than that of the control group,the difference was statistically significant( P<0.05). Conclusion The treatment of irinotecan plus Tegafur,Gimeracil and Oteracil Porassium Capsules in patients with advanced colorectal cancer is superior to irinotecan alone in improving the efficiency of clinical treatment and reducing the incidence of leukopenia and gastrointestinal reactions.
引文
[1]季华.FOLFOX4化疗联合自拟中药扶正消积汤治疗中晚期结肠癌疗效观察[J].现代中西医结合杂志,2016,25(21):2363-2365.
[2]陈幸运,周礼鲲,王霞,等.维持治疗在晚期结直肠癌化疗后达稳定患者中的价值及预后分析[J].中国肿瘤临床,2016,43(2):76-80.
[3]尹进南,徐进,岳茂兴,等.K-ras突变型晚期结直肠癌患者采用奥沙利铂或伊立替康联合氟尿嘧啶治疗的临床对比研究[J].临床和实验医学杂志,2017,16(9):73-76.
[4]左文丽,邓梅,尹青松,等.门冬酰胺酶联合GDP方案治疗结外NK/T细胞淋巴瘤的临床疗效观察[J].中国肿瘤临床,2017,44(7):321-323.
[5]Fiala O,Buchler T,Mohelnikova-DuchonowaB,et al.G12Vand G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab[J].Tumour Biol,2016,37(5):6823-6830.
[6]蔡红许,宋竹翠,林灵芝,等.替吉奥联合伊立替康或紫杉醇治疗晚期进展胃癌疗效分析[J].河北医药,2017,39(24):3754-3756.
[7]苏正曙,陈建望,孙余挺.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的临床分析[J].实用肿瘤杂志,2017,32(1):77-79.
[8]孟秋丽,吴晓邡.替吉奥单药治疗老年或体弱转移性结直肠癌患者疗效分析[J].肿瘤基础与临床,2016,29(1):39-42.
[9]周冬梅,韩正祥,杜秀平,等.替吉奥联合伊立替康治疗FOLFOX耐药的晚期结直肠癌的临床研究[J].肿瘤药学,2014,4(5):350-353.
[10]颜芳,孟荣荣.替吉奥胶囊联合伊立替康治疗晚期结直肠癌的临床观察[J].实用临床医药杂志,2013,17(1):70-72.
[11]焦勇.替吉奥联合伊立替康一线治疗晚期结直肠癌的前瞻性临床观察[J].北方药学,2016,13(1):16-17.
[2]陈幸运,周礼鲲,王霞,等.维持治疗在晚期结直肠癌化疗后达稳定患者中的价值及预后分析[J].中国肿瘤临床,2016,43(2):76-80.
[3]尹进南,徐进,岳茂兴,等.K-ras突变型晚期结直肠癌患者采用奥沙利铂或伊立替康联合氟尿嘧啶治疗的临床对比研究[J].临床和实验医学杂志,2017,16(9):73-76.
[4]左文丽,邓梅,尹青松,等.门冬酰胺酶联合GDP方案治疗结外NK/T细胞淋巴瘤的临床疗效观察[J].中国肿瘤临床,2017,44(7):321-323.
[5]Fiala O,Buchler T,Mohelnikova-DuchonowaB,et al.G12Vand G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab[J].Tumour Biol,2016,37(5):6823-6830.
[6]蔡红许,宋竹翠,林灵芝,等.替吉奥联合伊立替康或紫杉醇治疗晚期进展胃癌疗效分析[J].河北医药,2017,39(24):3754-3756.
[7]苏正曙,陈建望,孙余挺.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的临床分析[J].实用肿瘤杂志,2017,32(1):77-79.
[8]孟秋丽,吴晓邡.替吉奥单药治疗老年或体弱转移性结直肠癌患者疗效分析[J].肿瘤基础与临床,2016,29(1):39-42.
[9]周冬梅,韩正祥,杜秀平,等.替吉奥联合伊立替康治疗FOLFOX耐药的晚期结直肠癌的临床研究[J].肿瘤药学,2014,4(5):350-353.
[10]颜芳,孟荣荣.替吉奥胶囊联合伊立替康治疗晚期结直肠癌的临床观察[J].实用临床医药杂志,2013,17(1):70-72.
[11]焦勇.替吉奥联合伊立替康一线治疗晚期结直肠癌的前瞻性临床观察[J].北方药学,2016,13(1):16-17.